Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17260423 | 0.84 | PGK1 (0.34) | NUDT1 | |
| SCHEMBL3850941 | 0.82 | NUDT1 (0.31) | NUDT1 | |
| SCHEMBL13743173 | 0.71 | NUDT1 (0.30) | NUDT1 | |
| SCHEMBL3850933 | 0.70 | — | — | |
| SCHEMBL3850937 | 0.69 | — | — | |
| SCHEMBL2583995 | 0.67 | — | — | |
| SCHEMBL4860722 | 0.67 | — | — | |
| SCHEMBL18134202 | 0.66 | — | — | |
| SCHEMBL187063 | 0.66 | — | — | |
| SCHEMBL109050 | 0.66 | EPHX1 (0.35) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143007-B1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-9796686-B2 | Antibacterial quinazoline-4(3H)-one derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-03-23 | — | — | US | disclosed |
| EP-3143007-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173329-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081292-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | MRPL21, PYM1, MDK | NUDT1 2717/4885TSHR 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.